Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 18 de 18
1.
Clin Infect Dis ; 77(1): 38-45, 2023 07 05.
Article En | MEDLINE | ID: mdl-36905147

BACKGROUND: Invasive aspergillosis (IA) by a triazole-resistant Aspergillus fumigatus is associated with high mortality. Real-time resistance detection will result in earlier initiation of appropriate therapy. METHODS: In a prospective study, we evaluated the clinical value of the AsperGenius polymerase chain reaction (PCR) assay in hematology patients from 12 centers. This PCR assay detects the most frequent cyp51A mutations in A. fumigatus conferring azole resistance. Patients were included when a computed tomography scan showed a pulmonary infiltrate and bronchoalveolar fluid (BALf) sampling was performed. The primary end point was antifungal treatment failure in patients with azole-resistant IA. RESULTS: Of 323 patients enrolled, complete mycological and radiological information was available for 276 (94%), and probable IA was diagnosed in 99/276 (36%). Sufficient BALf for PCR testing was available for 293/323 (91%). Aspergillus DNA was detected in 116/293 (40%) and A. fumigatus DNA in 89/293 (30%). The resistance PCR was conclusive in 58/89 (65%) and resistance detected in 8/58 (14%). Two had a mixed azole-susceptible/azole-resistant infection. In the 6 remaining patients, treatment failure was observed in 1. Galactomannan positivity was associated with mortality (P = .004) while an isolated positive Aspergillus PCR was not (P = .83). CONCLUSIONS: Real-time PCR-based resistance testing may help to limit the clinical impact of triazole resistance. In contrast, the clinical impact of an isolated positive Aspergillus PCR on BALf seems limited. The interpretation of the EORTC/MSGERC PCR criterion for BALf may need further specification (eg, minimum cycle threshold value and/or PCR positive on >1 BALf sample).


Aspergillosis , Invasive Fungal Infections , Invasive Pulmonary Aspergillosis , Humans , Prospective Studies , Invasive Pulmonary Aspergillosis/diagnosis , Invasive Pulmonary Aspergillosis/drug therapy , Invasive Pulmonary Aspergillosis/microbiology , Azoles/pharmacology , Azoles/therapeutic use , Aspergillosis/diagnosis , Aspergillosis/drug therapy , Aspergillosis/microbiology , Aspergillus , Aspergillus fumigatus , Invasive Fungal Infections/diagnosis , Invasive Fungal Infections/drug therapy , Real-Time Polymerase Chain Reaction/methods , Triazoles/pharmacology , Triazoles/therapeutic use , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Drug Resistance, Fungal
2.
Science ; 376(6599): eabm6380, 2022 06 17.
Article En | MEDLINE | ID: mdl-35587511

The molecular basis of interindividual clinical variability upon infection with Staphylococcus aureus is unclear. We describe patients with haploinsufficiency for the linear deubiquitinase OTULIN, encoded by a gene on chromosome 5p. Patients suffer from episodes of life-threatening necrosis, typically triggered by S. aureus infection. The disorder is phenocopied in patients with the 5p- (Cri-du-Chat) chromosomal deletion syndrome. OTULIN haploinsufficiency causes an accumulation of linear ubiquitin in dermal fibroblasts, but tumor necrosis factor receptor-mediated nuclear factor κB signaling remains intact. Blood leukocyte subsets are unaffected. The OTULIN-dependent accumulation of caveolin-1 in dermal fibroblasts, but not leukocytes, facilitates the cytotoxic damage inflicted by the staphylococcal virulence factor α-toxin. Naturally elicited antibodies against α-toxin contribute to incomplete clinical penetrance. Human OTULIN haploinsufficiency underlies life-threatening staphylococcal disease by disrupting cell-intrinsic immunity to α-toxin in nonleukocytic cells.


Bacterial Toxins , Cri-du-Chat Syndrome , Endopeptidases , Haploinsufficiency , Hemolysin Proteins , Staphylococcal Infections , Staphylococcus aureus , Bacterial Toxins/immunology , Cri-du-Chat Syndrome/genetics , Cri-du-Chat Syndrome/immunology , Endopeptidases/genetics , Haploinsufficiency/genetics , Haploinsufficiency/immunology , Hemolysin Proteins/immunology , Host-Pathogen Interactions/genetics , Host-Pathogen Interactions/immunology , Humans , Immunity, Cellular/genetics , Necrosis , Staphylococcal Infections/genetics , Staphylococcal Infections/immunology , Staphylococcal Infections/pathology
3.
Perit Dial Int ; 41(1): 110-114, 2021 01.
Article En | MEDLINE | ID: mdl-32400305

Candida species form biofilms, facilitating adherence to peritoneal dialysis (PD) catheters and making them less susceptible to antifungal therapy. Therefore, the International Society for Peritoneal Dialysis recommends immediate PD catheter removal in case of Candida peritonitis. However, in 2007, our institution showed that Candida peritonitis could be successfully treated without catheter removal with a treatment strategy including amphotericin B as catheter lock. To confirm the efficacy and safety of this lock-based protocol, we evaluated the outcome of Candida peritonitis episodes since then. A retrospective, single-centre study was conducted in which we analysed all Candida peritonitis episodes in PD patients, treated with the lock-based protocol between July 2006 and March 2018. Eleven non-relapse Candida peritonitis episodes in 10 patients were treated with the lock-based protocol. Seven of the 11 episodes (64%) were cured without PD catheter removal (5 episodes cured immediately, 1 episode cured after an early relapse and 1 episode cured after a late relapse), in 2 episodes (18%) the catheter had to be removed, and two patients died (18%). This study confirms our previous findings that an amphotericin B lock-based protocol has potential to cure Candida peritonitis without PD catheter removal. However, further research is needed given the limitations of this study. Until that time, the lock-based Candida protocol could be used in patients who are not severely ill and in whom PD catheter removal is not desirable.


Peritoneal Dialysis , Peritonitis , Amphotericin B/therapeutic use , Candida , Catheters, Indwelling/adverse effects , Humans , Peritoneal Dialysis/adverse effects , Peritonitis/drug therapy , Peritonitis/etiology , Retrospective Studies
4.
Crit Care Med ; 49(1): 60-69, 2021 01 01.
Article En | MEDLINE | ID: mdl-33165029

OBJECTIVES: Although the Surviving Sepsis Campaign bundle recommends obtaining blood cultures within 1 hour of sepsis recognition, adherence is suboptimal in many settings. We, therefore, implemented routine blood culture collection for all nonelective ICU admissions (regardless of infection suspicion) and evaluated its diagnostic yield. DESIGN: A before-after analysis. SETTING: A mixed-ICU of a tertiary care hospital in the Netherlands. PATIENTS: Patients acutely admitted to the ICU between January 2015 and December 2018. MEASUREMENTS AND MAIN RESULTS: Automatic orders for collecting a single set of blood cultures immediately upon ICU admission were implemented on January 1, 2017. Blood culture results and the impact of contaminated blood cultures were compared for 2015-2016 (before period) and 2017-2018 (after period). Positive blood cultures were categorized as bloodstream infection or contamination. Blood cultures were obtained in 573 of 1,775 patients (32.3%) and in 1,582 of 1,871 patients (84.5%) in the before and after periods, respectively (p < 0.0001), and bloodstream infection was diagnosed in 95 patients (5.4%) and 154 patients (8.2%) in both study periods (relative risk 1.5; 95% CI 1.2-2.0; p = 0.0006). The estimated number needed to culture for one additional patient with bloodstream infection was 17. Blood culture contamination occurred in 40 patients (2.3%) and 180 patients (9.6%) in the before period and after period, respectively (relative risk 4.3; 95% CI 3.0-6.0; p < 0.0001). Rate of vancomycin use or presumed episodes of catheter-related bloodstream infections treated with antibiotics did not differ between both study periods. CONCLUSIONS: Implementation of routine blood cultures was associated with a 1.5-fold increase of detected bloodstream infection. The 4.3-fold increase in contaminated blood cultures was not associated with an increase in vancomycin use in the ICU.


Blood Culture , Critical Illness/therapy , Sepsis/microbiology , Aged , Blood Culture/methods , Blood Culture/statistics & numerical data , Female , Humans , Intensive Care Units/statistics & numerical data , Male , Middle Aged , Patient Admission , Prospective Studies , Sepsis/blood , Sepsis/diagnosis
5.
Dis Model Mech ; 13(9)2020 09 28.
Article En | MEDLINE | ID: mdl-32471891

Bacterial pathogens have evolved to secrete strong anti-inflammatory proteins that target the immune system. It was long speculated whether these virulence factors could serve as therapeutics in diseases in which abnormal immune activation plays a role. We adopted the secreted chemotaxis inhibitory protein of Staphylococcus aureus (CHIPS) as a model virulence factor-based therapeutic agent for diseases in which C5AR1 stimulation plays an important role. We show that the administration of CHIPS in human C5AR1 knock-in mice successfully dampens C5a-mediated neutrophil migration during immune complex-initiated inflammation. Subsequent CHIPS toxicology studies in animal models were promising. However, during a small phase I trial, healthy human volunteers showed adverse effects directly after CHIPS administration. Subjects showed clinical signs of anaphylaxis with mild leukocytopenia and increased C-reactive protein concentrations, which are possibly related to the presence of relatively high circulating anti-CHIPS antibodies and suggest an inflammatory response. Even though our data in mice show CHIPS as a potential anti-inflammatory agent, safety issues in human subjects temper the use of CHIPS in its current form as a therapeutic candidate. The use of staphylococcal proteins, or other bacterial proteins, as therapeutics or immune-modulators in humans is severely hampered by pre-existing circulating antibodies.


Antibodies, Bacterial/adverse effects , Bacterial Proteins/metabolism , Adolescent , Adult , Animals , Antigen-Antibody Complex/metabolism , Biomarkers/blood , Cell Movement , Complement C5a/metabolism , Disease Models, Animal , Healthy Volunteers , Humans , Male , Mast Cells/enzymology , Mice, Transgenic , Middle Aged , Neutrophils/metabolism , Receptor, Anaphylatoxin C5a/metabolism , Tryptases/blood , Young Adult
6.
Toxins (Basel) ; 12(2)2020 02 06.
Article En | MEDLINE | ID: mdl-32041354

Staphylococcal bi-component pore-forming toxins, also known as leukocidins, target and lyse human phagocytes in a receptor-dependent manner. S-components of the leukocidins Panton-Valentine leukocidin (PVL), γ-haemolysin AB (HlgAB) and CB (HlgCB), and leukocidin ED (LukED) specifically employ receptors that belong to the class of G-protein coupled receptors (GPCRs). Although these receptors share a common structural architecture, little is known about the conserved characteristics of the interaction between leukocidins and GPCRs. In this study, we investigated host cellular pathways contributing to susceptibility towards S. aureus leukocidin cytotoxicity. We performed a genome-wide CRISPR/Cas9 library screen for toxin-resistance in U937 cells sensitized to leukocidins by ectopic expression of different GPCRs. Our screen identifies post-translational modification (PTM) pathways involved in the sulfation and sialylation of the leukocidin-receptors. Subsequent validation experiments show differences in the impact of PTM moieties on leukocidin toxicity, highlighting an additional layer of refinement and divergence in the staphylococcal host-pathogen interface. Leukocidin receptors may serve as targets for anti-staphylococcal interventions and understanding toxin-receptor interactions will facilitate the development of innovative therapeutics. Variations in the genes encoding PTM pathways could provide insight into observed differences in susceptibility of humans to infections with S. aureus.


Host Microbial Interactions/genetics , Leukocidins/toxicity , Protein Processing, Post-Translational , Receptors, G-Protein-Coupled/metabolism , Staphylococcal Infections/pathology , Staphylococcus aureus/pathogenicity , CRISPR-Cas Systems , Cell Culture Techniques , Cell Survival/genetics , Drug Resistance, Bacterial/genetics , Genetic Predisposition to Disease , Genome-Wide Association Study , HEK293 Cells , Humans , Leukocidins/genetics , Leukocidins/metabolism , Phagocytes/microbiology , Phagocytes/pathology , Protein Binding , Receptors, G-Protein-Coupled/genetics , Staphylococcal Infections/microbiology , Staphylococcus aureus/genetics , Staphylococcus aureus/metabolism , U937 Cells
8.
Nat Microbiol ; 3(10): 1187, 2018 Oct.
Article En | MEDLINE | ID: mdl-30177744

In the version of this Article originally published, the name of author Robert Jan Lebbink was coded wrongly, resulting in it being incorrect when exported to citation databases. This has now been corrected, though no visible changes will be apparent.

9.
Cell Microbiol ; 20(11): e12941, 2018 Nov.
Article En | MEDLINE | ID: mdl-30098280

Staphylococcal superantigen-like (SSL) proteins, one of the major virulence factor families produced by Staphylococcus aureus, were previously demonstrated to be immune evasion molecules that interfere with a variety of innate immune defences. However, in contrast to characterised SSLs, which inhibit immune functions, we show that SSL13 is a strong activator of neutrophils via the formyl peptide receptor 2 (FPR2). Moreover, our data show that SSL13 acts as a chemoattractant and induces degranulation and oxidative burst in neutrophils. As with many other staphylococcal immune evasion proteins, SSL13 shows a high degree of human specificity. SSL13 is not able to efficiently activate mouse neutrophils, hampering in vivo experiments. In conclusion, SSL13 is a neutrophil chemoattractant and activator that acts via FPR2. Therefore, SSL13 is a unique SSL member that does not belong to the immune evasion class but is a pathogen alarming molecule. Our study provides a new concept of SSLs; SSLs not only inhibit host immune processes but also recruit human neutrophils to the site of infection. This new insight allows us to better understand complex interactions between host and S. aureus pathological processes.


Bacterial Proteins/metabolism , Neutrophils/microbiology , Receptors, Formyl Peptide/metabolism , Receptors, Lipoxin/metabolism , Staphylococcus aureus/pathogenicity , Virulence Factors/metabolism , Animals , Bacterial Proteins/genetics , Cell Degranulation , Chemotactic Factors/metabolism , Female , HL-60 Cells , Humans , Immune Evasion , Mice, Inbred Strains , Neutrophil Activation , Neutrophils/physiology , Peritonitis/metabolism , Peritonitis/microbiology , Respiratory Burst , Staphylococcal Infections/microbiology , Staphylococcal Infections/pathology
10.
Nat Microbiol ; 3(6): 708-717, 2018 06.
Article En | MEDLINE | ID: mdl-29736038

The staphylococcal bi-component leukocidins Panton-Valentine leukocidin (PVL) and γ-haemolysin CB (HlgCB) target human phagocytes. Binding of the toxins' S-components to human complement C5a receptor 1 (C5aR1) contributes to cellular tropism and human specificity of PVL and HlgCB. To investigate the role of both leukocidins during infection, we developed a human C5aR1 knock-in (hC5aR1KI) mouse model. HlgCB, but unexpectedly not PVL, contributed to increased bacterial loads in tissues of hC5aR1KI mice. Compared to humans, murine hC5aR1KI neutrophils showed a reduced sensitivity to PVL, which was mediated by the toxin's F-component LukF-PV. By performing a genome-wide CRISPR-Cas9 screen, we identified CD45 as a receptor for LukF-PV. The human-specific interaction between LukF-PV and CD45 provides a molecular explanation for resistance of hC5aR1KI mouse neutrophils to PVL and probably contributes to the lack of a PVL-mediated phenotype during infection in these mice. This study demonstrates an unsuspected role of the F-component in driving the sensitivity of human phagocytes to PVL.


Bacterial Toxins/metabolism , Exotoxins/metabolism , Leukocidins/metabolism , Leukocyte Common Antigens/metabolism , Receptor, Anaphylatoxin C5a/genetics , Staphylococcal Infections/microbiology , Staphylococcus aureus/pathogenicity , Animals , Bacterial Load , Bacterial Proteins/metabolism , CRISPR-Cas Systems , Cell Line , Disease Models, Animal , Hemolysin Proteins/metabolism , Humans , Mice , Mice, Knockout , Neutrophils/metabolism , Staphylococcal Infections/genetics , Staphylococcal Infections/immunology , Staphylococcal Infections/metabolism , Staphylococcus aureus/metabolism
11.
Mycoses ; 61(9): 656-664, 2018 Sep.
Article En | MEDLINE | ID: mdl-29687483

Patients with haematological malignancies are at risk for invasive fungal diseases (IFD). A survey was conducted in all Dutch academic haematology centres on their current diagnostic, prophylactic and therapeutic approach towards IFD in the context of azole-resistance. In all 8 centres, a haematologist and microbiologist filled in the questionnaire that focused on different subgroups of haematology patients. Fungal prophylaxis during neutropaenia was directed against Candida and consisted of fluconazole and/or amphotericin B suspension. Mould-active prophylaxis was given to acute myeloid leukaemia patients during chemotherapy in 2 of 8 centres. All centres used azole prophylaxis in a subset of patients with graft-versus-host disease. A uniform approach towards the diagnosis and treatment of IFD and in particular azole-resistant Aspergillus fumigatus was lacking. In 2017, all centres agreed to implement a uniform diagnostic and treatment algorithm regarding invasive aspergillosis with a central role for comprehensive diagnostics and PCR-based detection of azole-resistance. This study (DB-MSG 002) will re-evaluate this algorithm when 280 patients have been treated. A heterogeneous approach towards antifungal prophylaxis, diagnosis and treatment was apparent in the Netherlands. Facing triazole-resistance, consensus was reached on the implementation of a uniform diagnostic approach in all 8 centres.


Antifungal Agents/administration & dosage , Azoles/administration & dosage , Disease Management , Drug Resistance, Fungal , Hematologic Neoplasms/complications , Invasive Pulmonary Aspergillosis/diagnosis , Invasive Pulmonary Aspergillosis/drug therapy , Academic Medical Centers , Antifungal Agents/pharmacology , Aspergillus fumigatus/drug effects , Azoles/pharmacology , Chemoprevention/methods , Humans , Invasive Pulmonary Aspergillosis/prevention & control , Netherlands , Prevalence , Surveys and Questionnaires
12.
Proc Natl Acad Sci U S A ; 114(35): 9439-9444, 2017 08 29.
Article En | MEDLINE | ID: mdl-28808028

Staphylococcus aureus is highly adapted to its host and has evolved many strategies to resist opsonization and phagocytosis. Even after uptake by neutrophils, S. aureus shows resistance to killing, which suggests the presence of phagosomal immune evasion molecules. With the aid of secretome phage display, we identified a highly conserved protein that specifically binds and inhibits human myeloperoxidase (MPO), a major player in the oxidative defense of neutrophils. We have named this protein "staphylococcal peroxidase inhibitor" (SPIN). To gain insight into inhibition of MPO by SPIN, we solved the cocrystal structure of SPIN bound to a recombinant form of human MPO at 2.4-Å resolution. This structure reveals that SPIN acts as a molecular plug that prevents H2O2 substrate access to the MPO active site. In subsequent experiments, we observed that SPIN expression increases inside the neutrophil phagosome, where MPO is located, compared with outside the neutrophil. Moreover, bacteria with a deleted gene encoding SPIN showed decreased survival compared with WT bacteria after phagocytosis by neutrophils. Taken together, our results demonstrate that S. aureus secretes a unique proteinaceous MPO inhibitor to enhance survival by interfering with MPO-mediated killing.


Peroxidase/antagonists & inhibitors , Bacterial Proteins , Gene Expression Regulation, Bacterial , Humans , Models, Molecular , Neutrophils/physiology , Phagocytosis , Protein Binding , Protein Conformation , Staphylococcus aureus/metabolism , Up-Regulation
13.
Front Microbiol ; 7: 438, 2016.
Article En | MEDLINE | ID: mdl-27092115

Representatives of the genus Aspergillus are opportunistic fungal pathogens. Their conidia can reach the alveoli by inhalation and can give rise to infections in immunocompromised individuals. Aspergillus fumigatus is the causal agent of invasive aspergillosis in nearly 90% of the cases. It is not yet well-established what makes this fungus more pathogenic than other aspergilli such as A. niger. Here, we show that A. fumigatus and A. niger conidia adhere with similar efficiency to lung epithelial A549 cells but A. fumigatus conidia internalized 17% more efficiently. Conidia of both aspergilli were taken up in phagolysosomes 8 h after the challenge. These organelles only acidified in the case of A. niger, which is probably due to the type of melanin coating of the conidia. Viability of both types of conidia was not affected after uptake in the phagolysosomes. Germination of A. fumigatus and A. niger conidia in the presence of epithelial cells was delayed when compared to conidia in the medium. However, germination of A. niger conidia was still higher than that of A. fumigatus 10 h after exposure to A549 cells. Remarkably, A. fumigatus hyphae grew mainly parallel to the epithelium, while growth direction of A. niger hyphae was predominantly perpendicular to the plane of the cells. Neutrophils reduced germination and hyphal growth of A. niger, but not of A fumigatus, in presence of epithelial cells. Taken together, efficient internalization, delayed germination, and hyphal growth parallel to the epithelium gives a new insight into what could be the causes for the success of A. fumigatus compared to A. niger as an opportunistic pathogen in the lung.

14.
Case Rep Infect Dis ; 2015: 504975, 2015.
Article En | MEDLINE | ID: mdl-26346659

Immunocompromised patients are at increased risk of complications of influenza virus infection. We report on two critically ill patients on immunosuppressive medication with influenza pneumonia. In both patients, oseltamivir monotherapy did not result in clearance of the virus after 18 and five days, respectively. After adding zanamivir and amantadine to the treatment, PCRs on pharyngeal and/or plasma specimens turned negative in both patients after four and three days, respectively. We suggest, that in critically ill patients with influenza A H1N1 infection, treatment efficacy should be monitored closely and treatment with a combination of antiviral drugs should be considered.

15.
J Innate Immun ; 7(4): 364-74, 2015.
Article En | MEDLINE | ID: mdl-25676601

Aspergillus fumigatus is an important airborne fungal pathogen and a major cause of invasive fungal infections. Susceptible individuals become infected via the inhalation of dormant conidia. If the immune system fails to clear these conidia, they will swell, germinate and grow into large hyphal structures. Neutrophils are essential effector cells for controlling A. fumigatus infection. In general, opsonization of microbial particles is crucial for efficient phagocytosis and killing by neutrophils. Although the antibodies present in human serum do bind to all fungal morphotypes, we observed no direct antibody-mediated phagocytosis of A. fumigatus. We show that opsonization, phagocytosis and killing by neutrophils of A. fumigatus is complement-dependent. Using human sera depleted of key complement components, we investigated the contribution of the different complement initiation pathways in complement activation on the fungal surface. We describe the classical complement pathway as the main initiator of complement activation on A. fumigatus swollen conidia and germ tubes. Antibodies play an important role in complement activation and efficient innate recognition, phagocytosis and killing of A. fumigatus by neutrophils.


Aspergillosis/immunology , Aspergillus fumigatus/immunology , Complement Pathway, Classical/immunology , Neutrophils/immunology , Phagocytosis , Aspergillosis/pathology , Humans , Neutrophils/pathology
16.
Cell Microbiol ; 16(11): 1646-65, 2014 Nov.
Article En | MEDLINE | ID: mdl-24840181

In order to cause colonization and invasive disease, pathogenic bacteria secrete proteins that modulate host immune defences. Identification and characterization of these proteins leads to a better understanding of the pathological processes underlying infectious and inflammatory diseases and is essential in the development of new strategies for their prevention and treatment. Current techniques to functionally characterize these proteins are laborious and inefficient. Here we describe a high-throughput functional selection strategy using phage display in order to identify immune evasion proteins. Using this technique we identified two previously uncharacterized proteins secreted by Staphylococcus aureus, SElX and SSL6 that bind to neutrophil surface receptors. SElX binds PSGL-1 on neutrophils and thereby inhibits the interaction between PSGL-1 and P-selectin, a crucial step in the recruitment of neutrophils to the site of infection. SSL6 is the first bacterial protein identified that binds CD47, a widely expressed cell surface protein recently described as an interesting target in anti-cancer therapy. Our findings provide new insights into the pathogenesis of S. aureus infections and support phage display as an efficient method to identify bacterial secretome proteins interacting with humoral or cellular immune components.


Bacterial Proteins/metabolism , Cell Surface Display Techniques/methods , Host-Pathogen Interactions , Membrane Proteins/metabolism , Neutrophils/microbiology , Staphylococcus aureus/physiology , CD47 Antigen , Membrane Glycoproteins
18.
Eur J Haematol ; 87(5): 419-25, 2011 Nov.
Article En | MEDLINE | ID: mdl-21732981

OBJECTIVES: Invasive mold infections (IMI) are an important cause of morbidity and mortality in patients with hematological malignancies. Cumulative incidence numbers vary greatly, probably because local circumstances influence the incidence of IMI. Therefore, comparison of different patient groups at risk should be performed at one hospital. METHODS: We performed a single-center retrospective analysis examining both adult patients treated with chemotherapy for acute leukemia or MDS and patients undergoing allogeneic or autologous stem cell transplantation (SCT) between June 2007 and August 2009. IMI were classified according to the EORTC criteria. RESULTS: A total of 211 patients with 237 predefined risk episodes were analyzed. A total of 22 IMI were observed: three of them were classified as proven, 15 as probable, and four as possible. No IMI were observed in the autologous SCT group. The incidence of proven and probable IMI in the allogeneic SCT group was 7.2%, and in the chemotherapy group, 14.3%. Patients with IMI had a higher mortality risk. CONCLUSIONS: We demonstrate for the first time that patients receiving intensive chemotherapy for acute leukemia have the highest risk of developing IMI during their treatment compared to patients with allogeneic SCT.


Leukemia/drug therapy , Mycoses/epidemiology , Stem Cell Transplantation , Adolescent , Adult , Aged , Female , Humans , Leukemia/complications , Male , Middle Aged , Mycoses/complications , Retrospective Studies , Young Adult
...